PlainRecalls
FDA Drug Moderate Class II Ongoing

Glenmark Ranitidine Tablets USP 300 mg Rx Only 30 Tablets Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bandez, Goa 403513, India Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ NDC 68462-249-30

Reported: January 15, 2020 Initiated: December 17, 2019 #D-0641-2020

Product Description

Glenmark Ranitidine Tablets USP 300 mg Rx Only 30 Tablets Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bandez, Goa 403513, India Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ NDC 68462-249-30

Reason for Recall

CGMP Deviations: Presence of NDMA impurity detected in product.

Details

Units Affected
98,988 bottles
Distribution
Natiowide
Location
Mahwah, NJ

Frequently Asked Questions

What product was recalled?
Glenmark Ranitidine Tablets USP 300 mg Rx Only 30 Tablets Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bandez, Goa 403513, India Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ NDC 68462-249-30. Recalled by Glenmark Pharmaceuticals Inc., USA. Units affected: 98,988 bottles.
Why was this product recalled?
CGMP Deviations: Presence of NDMA impurity detected in product.
Which agency issued this recall?
This recall was issued by the FDA Drug on January 15, 2020. Severity: Moderate. Recall number: D-0641-2020.